BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...neuromuscular and pulmonary diseases, hired Andrew Smith as CFO. He was CFO and COO at Allecra Therapeutics GmbH...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

...Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at Allecra Therapeutics GmbH...
BioCentury | Mar 30, 2018
Clinical News

Allecra reports Phase II data for AAI101 combo to treat cUTI

...mg IV AAI101 plus cefepime or cefepime alone given three times daily for 7-10 days. Allecra...
...the infection is needed, vs. 93% (14/15) of patients who received cefepime alone. Next half, Allecra...
...treat cUTIs, complicated intra-abdominal infections (cIAIs), hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Allecra Therapeutics GmbH...
BioCentury | Mar 2, 2018
Financial News

BioMedPartners closes third fund at CHF100M

...fund has invested in Cardior Pharmaceuticals GmbH (Hannover, Germany), Amal Therapeutics S.A. (Geneva, Switzerland) and Allecra Therapeutics GmbH...
...$74 million), and BioMedInvest II in 2009 at CHF106 million ($104.2 million). BioMedPartners, Basel, Switzerland Allison Johnson Allecra Therapeutics GmbH Amal...
BioCentury | Mar 1, 2018
Financial News

BioMedPartners closes third fund

...fund has invested in Cardior Pharmaceuticals GmbH (Hannover, Germany), Amal Therapeutics S.A. (Geneva, Switzerland) and Allecra Therapeutics GmbH...
...at CHF100 million ($74 million), and BioMedInvest II in 2009 at CHF106 million ($104.2 million). Allison Johnson Allecra Therapeutics GmbH Amal...
BioCentury | Apr 6, 2017
Company News

Management tracks

...continue as a part-time professor at the University of Pittsburgh School of Medicine. Antibiotic company Allecra Therapeutics GmbH...
BioCentury | Jun 20, 2016
Financial News

Allecra completes venture financing

Allecra Therapeutics GmbH , Lorrach, Germany Business: Infectious Date completed: 2016-06-15 Type: Venture financing Raised: EUR22 million ($24.8 million) Investors: Delos Capital; Forbion Capital Partners; Edmond de Rothschild Investment Partners; EMBL Ventures; company founder WIR Staff...
BioCentury | Jun 16, 2016
Financial News

Antibiotic play Allecra raises EUR 22M

...de Rothschild Investment Partners, EMBL Ventures and Allecra co-founder and CEO Nicholas Benedict also participated. Allecra...
...cUTIs), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). AAI202 combines cephalosporin antibiotic cefepime with AAI101, Allecra's...
...common driver of bacteria mediated-resistance in a hospital setting. Benedict said the round will give Allecra...
BioCentury | Feb 20, 2014
Cover Story

Europe's upwelling

...million. The London-based biotech is developing therapies to treat viral and fungal respiratory tract infections. Allecra Therapeutics GmbH...
...& Lou, K.-J. SciBX 7(7); doi:10.1038/scibx.2014.188 Published online Feb. 20, 2014 Companies and Institutions Mentioned Allecra Therapeutics GmbH...
...Infectious disease London, U.K. $27.4 Envisia Therapeutics Inc. Ophthalmic disease Research Triangle Park, N.C. $25.0 Allecra Therapeutics GmbH...
BioCentury | Nov 4, 2013
Finance

Rothschild racks up

...investments. The firm co-led a €15 million ($19.6 million) A round for preclinical antibiotics company Allecra...
...under management, split between life science funds and growth capital funds. Companies and Institutions Mentioned Allecra...
Items per page:
1 - 10 of 13
BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...neuromuscular and pulmonary diseases, hired Andrew Smith as CFO. He was CFO and COO at Allecra Therapeutics GmbH...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

...Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at Allecra Therapeutics GmbH...
BioCentury | Mar 30, 2018
Clinical News

Allecra reports Phase II data for AAI101 combo to treat cUTI

...mg IV AAI101 plus cefepime or cefepime alone given three times daily for 7-10 days. Allecra...
...the infection is needed, vs. 93% (14/15) of patients who received cefepime alone. Next half, Allecra...
...treat cUTIs, complicated intra-abdominal infections (cIAIs), hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Allecra Therapeutics GmbH...
BioCentury | Mar 2, 2018
Financial News

BioMedPartners closes third fund at CHF100M

...fund has invested in Cardior Pharmaceuticals GmbH (Hannover, Germany), Amal Therapeutics S.A. (Geneva, Switzerland) and Allecra Therapeutics GmbH...
...$74 million), and BioMedInvest II in 2009 at CHF106 million ($104.2 million). BioMedPartners, Basel, Switzerland Allison Johnson Allecra Therapeutics GmbH Amal...
BioCentury | Mar 1, 2018
Financial News

BioMedPartners closes third fund

...fund has invested in Cardior Pharmaceuticals GmbH (Hannover, Germany), Amal Therapeutics S.A. (Geneva, Switzerland) and Allecra Therapeutics GmbH...
...at CHF100 million ($74 million), and BioMedInvest II in 2009 at CHF106 million ($104.2 million). Allison Johnson Allecra Therapeutics GmbH Amal...
BioCentury | Apr 6, 2017
Company News

Management tracks

...continue as a part-time professor at the University of Pittsburgh School of Medicine. Antibiotic company Allecra Therapeutics GmbH...
BioCentury | Jun 20, 2016
Financial News

Allecra completes venture financing

Allecra Therapeutics GmbH , Lorrach, Germany Business: Infectious Date completed: 2016-06-15 Type: Venture financing Raised: EUR22 million ($24.8 million) Investors: Delos Capital; Forbion Capital Partners; Edmond de Rothschild Investment Partners; EMBL Ventures; company founder WIR Staff...
BioCentury | Jun 16, 2016
Financial News

Antibiotic play Allecra raises EUR 22M

...de Rothschild Investment Partners, EMBL Ventures and Allecra co-founder and CEO Nicholas Benedict also participated. Allecra...
...cUTIs), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). AAI202 combines cephalosporin antibiotic cefepime with AAI101, Allecra's...
...common driver of bacteria mediated-resistance in a hospital setting. Benedict said the round will give Allecra...
BioCentury | Feb 20, 2014
Cover Story

Europe's upwelling

...million. The London-based biotech is developing therapies to treat viral and fungal respiratory tract infections. Allecra Therapeutics GmbH...
...& Lou, K.-J. SciBX 7(7); doi:10.1038/scibx.2014.188 Published online Feb. 20, 2014 Companies and Institutions Mentioned Allecra Therapeutics GmbH...
...Infectious disease London, U.K. $27.4 Envisia Therapeutics Inc. Ophthalmic disease Research Triangle Park, N.C. $25.0 Allecra Therapeutics GmbH...
BioCentury | Nov 4, 2013
Finance

Rothschild racks up

...investments. The firm co-led a €15 million ($19.6 million) A round for preclinical antibiotics company Allecra...
...under management, split between life science funds and growth capital funds. Companies and Institutions Mentioned Allecra...
Items per page:
1 - 10 of 13